- Avinger Inc. (NASDAQ:AVGR) launched its Tigereye ST next generation image-guided chronic total occlusion (CTO) crossing system
- This is the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease
- Avinger’s Lumivascular technology incorporates an onboard image-guidance system to allow physicians to see inside the artery during an atherectomy or CTO-crossing procedure by using an imaging modality called optical coherence tomography
- Avinger Inc. last traded at US$6.07 per share
Avinger Inc. (NASDAQ:AVGR) launched its Tigereye ST next generation image-guided chronic total occlusion (CTO) crossing system.
This is the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease.
Before the full commercial launch, the health care company conducted a limited launch at 11 clinical centres in the United States, where 50 CTO procedures were performed with Tigereye ST by 13 physicians.
Avinger’s Lumivascular technology incorporates an onboard image-guidance system to allow physicians to see inside the artery during an atherectomy or CTO-crossing procedure by using an imaging modality called optical coherence tomography (OCT).
Tigereye ST features high definition, real-time intravascular imaging and a user-controlled deflectable tip designed to assist in steering. The device also includes an enhanced distal tip configuration with faster rotational speeds up to 1000 RPM designed to penetrate challenging lesions.
“This device represents one of the most significant advancements in Avinger’s image-guided technologies for the treatment of peripheral artery disease,” Avinger’s chief medical officer, Dr. Jaafer Golzar said in a news release. “Tigereye ST incorporates a robust new distal tip design to cross longer and more complex lesions and device features to make image interpretation easier, building on the enhanced imaging, higher rotational speeds, and precise user-control of the Tigereye platform. The unique combination of onboard image-guidance, steerability, ease of use, and crossing power expands the number of patients eligible for minimally invasive revascularization.”
Avinger Inc. is a commercial-stage medical device company that designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters.
Avinger Inc. last traded at US$6.07 per share, up 88 per cent in post-market trading. In the past week, AVGR stock has risen 1,303.23 per cent.
Join the discussion: Find out what everybody’s saying about this stock on the Avinger Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
